Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher W Ryan

Showing results (51-60 of 113) with videos related to

Pageof 12
Sort By:
British Journal of Haematology|September 21, 2006
High dose calcitriol may reduce thrombosis in cancer patientsTomasz M Beer, Peter M Venner, Christopher W Ryan, et al.
Cancer|October 27, 2007
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxelTomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
Cancer|March 19, 2008
Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomasChristopher W Ryan, Anthony G Montag, Janet R Hosenpud, et al.
Sarcoma|June 15, 2013
MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing RhabdomyosarcomaKen Kikuchi, George R Wettach, Christopher W Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignanciesChristopher W Ryan, Nicholas J Vogelzang, Everett E Vokes, et al.
Investigational New Drugs|April 28, 2012
A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcomaChristopher W Ryan, Chacon Matias, Mark Agulnik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology GroupChristopher W Ryan, Bryan H Goldman, Primo N Lara, et al.
Cancer|April 23, 2008
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trialTomasz M Beer, Alshad S Lalani, Stella Lee, et al.
Journal for Immunotherapy of Cancer|July 27, 2024
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohortSandip P Patel, Megan Othus, Young Kwang Chae, et al.
Annals of Surgical Oncology|February 2, 2018
Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue SarcomasEric Lu, Kelly S Perlewitz, James B Hayden, et al.
Pageof 12

Showing results (51-60 of 113) with videos related to

Sort By:
Pageof 12
British Journal of Haematology|September 21, 2006
High dose calcitriol may reduce thrombosis in cancer patientsTomasz M Beer, Peter M Venner, Christopher W Ryan, et al.
Cancer|October 27, 2007
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxelTomasz M Beer, Christopher W Ryan, Peter M Venner, et al.
Cancer|March 19, 2008
Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomasChristopher W Ryan, Anthony G Montag, Janet R Hosenpud, et al.
Sarcoma|June 15, 2013
MDM2 Amplification and PI3KCA Mutation in a Case of Sclerosing RhabdomyosarcomaKen Kikuchi, George R Wettach, Christopher W Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2004
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignanciesChristopher W Ryan, Nicholas J Vogelzang, Everett E Vokes, et al.
Investigational New Drugs|April 28, 2012
A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcomaChristopher W Ryan, Chacon Matias, Mark Agulnik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology GroupChristopher W Ryan, Bryan H Goldman, Primo N Lara, et al.
Cancer|April 23, 2008
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trialTomasz M Beer, Alshad S Lalani, Stella Lee, et al.
Journal for Immunotherapy of Cancer|July 27, 2024
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohortSandip P Patel, Megan Othus, Young Kwang Chae, et al.
Annals of Surgical Oncology|February 2, 2018
Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue SarcomasEric Lu, Kelly S Perlewitz, James B Hayden, et al.
Pageof 12